Full Year 2024 Pharmx Technologies Ltd Earnings Call Transcript
Key Points
- PharmX Technologies Ltd (ASX:PHX) reported a 9% growth in revenues and a 13% growth in earnings for FY24.
- The company maintains a strong cash position, even after paying out a $9.9 million court settlement.
- PharmX Technologies Ltd (ASX:PHX) successfully sold its pharmacy software business, generating $6.25 million in proceeds.
- The company has secured exclusive partnerships in beauty and nicotine vaping products, expected to drive significant revenues.
- PharmX Technologies Ltd (ASX:PHX) has a high market penetration, with 99% of Australian pharmacies using its offerings.
- The company faced a $1.8 million statutory net loss for FY24, partly due to the legal case settlement and the sale of the pharmacy software business.
- Despite revenue growth, statutory costs grew by 15%, impacting overall profitability.
- The sale of the pharmacy software business resulted in a net loss of $1.864 million.
- The company is still in the early stages of its marketplace platform, which is not yet generating significant revenue.
- PharmX Technologies Ltd (ASX:PHX) had to absorb corporate overheads previously allocated to the sold pharmacy software business, affecting EBITDA.
My name is Tom Culver. I'm the CEO of PharmX. And today, we'll be taking you through a couple of key areas in our presentation, an overview of the business today, our results, and (technical difficulty) FY25. I'll hand it over to Jon to introduce himself.
Morning, everyone. I'm Jon Newbery. As many of you know, I'm standing in for Zoe Hillier, who's away on maternity leave, as the CFO. And I'm delighted to be here this morning and look forward to talking you through the financial results for the financial year ended June 30, 2024, little bit later.
Thank you, Jon. And then, just a last comment you can hold any questions until the end. We've got plenty of time for Q&A. Please feel free to put in (technical difficulty), we'll address those as we go. And if everybody could kindly
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
